Literature DB >> 23265763

Patient awareness of extraintestinal manifestations of inflammatory bowel disease.

Vivian Huang1, Ravi Mishra, Reka Thanabalan, Geoffrey C Nguyen.   

Abstract

INTRODUCTION: Patient awareness of extraintestinal manifestations of inflammatory bowel diseases is important in improving patient understanding of their disease and health outcomes. We aim to characterize patient awareness of extraintestinal complications related to their disease.
METHODS: A cross-sectional survey was administered from July 2011 to May 2012. All adult (>18 years) IBD patients attending gastroenterology clinics at a major tertiary teaching hospital (Mount Sinai Hospital, Toronto, ON, Canada) with a confirmed diagnosis of inflammatory bowel disease were invited to participate.
RESULTS: A total of 299 patients participated: 177 Crohn's disease, 104 ulcerative colitis, and 18 IBD-unclassified. The vast majority of respondents obtained their information from their gastroenterologist (92%) and from the internet (78%). Most patients felt their inflammatory bowel disease knowledge was "very good" (34%) or "enough to get by" (54%). Most patients were aware of risk of colon cancer (75%), arthritis (77%), dermatological manifestations (49%), ocular inflammation (47%), and osteoporosis (53%). However, few patients were aware of venous thromboembolism (18%), nephrolithiasis (12%), or primary sclerosing cholangitis (20%). The majority of respondents were unsure of the signs and symptoms of venous thromboembolism, that the risk was increased during flares and hospitalizations, and that they require prophylaxis during an inflammatory bowel disease-related hospitalization.
CONCLUSION: Although the majority of respondents demonstrated awareness of most extraintestinal manifestations, few realized that venous thromboembolism was a life-threatening systemic complication of inflammatory bowel disease. Greater knowledge of venous thromboembolism would enable patients to more promptly seek potentially life-saving intervention.
Copyright © 2012 European Crohn's and Colitis Organisation. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Crohn's disease; EIM; Extraintestinal manifestation; IBD; Inflammatory bowel disease; Ulcerative colitis; VTE; Venous thromboembolism; extraintestinal manifestation; inflammatory bowel disease; venous thromboembolism

Mesh:

Year:  2012        PMID: 23265763     DOI: 10.1016/j.crohns.2012.11.008

Source DB:  PubMed          Journal:  J Crohns Colitis        ISSN: 1873-9946            Impact factor:   9.071


  6 in total

1.  Achilles tendinitis as a rare extraintestinal manifestation of ulcerative colitis.

Authors:  Takahiro Zenda; Ichiro Araki; Otoyuki Nakamiya; Yuji Tokuumi; Yuka Shimada; Keigo Komai; Yukie Taniuchi
Journal:  Clin J Gastroenterol       Date:  2016-04-08

Review 2.  Inflammatory bowel disease and thromboembolism.

Authors:  Petros Zezos; Georgios Kouklakis; Fred Saibil
Journal:  World J Gastroenterol       Date:  2014-10-14       Impact factor: 5.742

3.  Urolithiasis in inflammatory bowel disease and bariatric surgery.

Authors:  Agapios Gkentzis; Michael Kimuli; Jon Cartledge; Olivier Traxer; Chandra Shekhar Biyani
Journal:  World J Nephrol       Date:  2016-11-06

Review 4.  Ophthalmic manifestations in patients with inflammatory bowel disease: A review.

Authors:  Leandro Lopes Troncoso; Ana Luiza Biancardi; Haroldo Vieira de Moraes; Cyrla Zaltman
Journal:  World J Gastroenterol       Date:  2017-08-28       Impact factor: 5.742

5.  Pulmonary dysfunction in 114 patients with inflammatory bowel disease.

Authors:  Yujie Zhao; Junshan Wang; Zhanju Liu; Hui Lin; Yanhong Shi; Xiaomin Sun
Journal:  Medicine (Baltimore)       Date:  2017-05       Impact factor: 1.889

6.  Information Needs and Concerns of Patients with Inflammatory Bowel Disease: What Can We Learn from Participants in a Bilingual Clinical Cohort?

Authors:  Valérie Pittet; Carla Vaucher; Michel H Maillard; Marc Girardin; Philippe de Saussure; Bernard Burnand; Gerhard Rogler; Pierre Michetti
Journal:  PLoS One       Date:  2016-03-03       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.